Prof Barry Hunt

Professor Barry Hunt has been a trustee of Ataxia UK since 1999. He chaired its Scientific Advisory Committee from its inception in 2000 until March 2012, and continues to be the Committee’s link with the Board of Trustees.

Barry has a doctorate in pharmacology, and was appointed Dean of the Faculty of Health and Human Sciences of the University of Hertfordshire in 2005, and its Pro-Vice-Chancellor in 2009, positions which he still holds. In addition, he is Chairman of the university’s ethics committee. He has had a long-term association with the review of clinical trials and now chairs a National Research Ethic Service (NRES) ethics committee. He is also a Member of the Royal Pharmaceutical Society of Great Britain and of the British Pharmacological Society. He is currently a shadow governor and member of the Involvement Committee of the East and North Hertfordshire NHS Trust, and has previously held numerous other governance roles in health and education.

Barry in indispensable in assisting Ataxia UK's Research department to take part in our bi-annual International Ataxia Research Conference.

Latest

The Big Christmas Challenge 2019 resources

After the huge success of the Big Give Christmas Challenge in 2018, will you join again to improve access to ataxia specialist care across the country?
The UK's first Ataxia Centre for Children!

Thanks to your generous giving to the Big Give last year, we are ecstatic to announce the first Ataxia Specialist Centre for children
Minoryx Therapeutics granted FDA Orphan Drug Designation in Friedreich’s Ataxia for new drug leriglitazone

Minoryx Therapeutics has announced that its lead drug candidate, leriglitazone (MIN-102), has been given an Orphan Drug Designation for Friedreich’s Ataxia by the US Food and Drug Administration (FDA).
DWP consultations to ask disabled people how the social security system could better support their needs